

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antioxidant	placebo	Relative (95% CI)	Absolute (95% CI)		
Mental health (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: DMR [sum of cognitive scores])												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	No significant differences in DMR cognitive scores scores between antioxidant and placebo groups				⊕⊕○○ LOW	CRITICAL
Mental health (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: Severe impairment battery)												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	No significant differences in Severe Impairment Battery scores between antioxidant and placebo groups				⊕⊕○○ LOW	CRITICAL

Mental health problems in people with learning disabilities  
 Appendix N: GRADE evidence profiles for all studies

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antioxidant	placebo	Relative (95% CI)	Absolute (95% CI)		
Quality of life – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Community participation and meaningful occupation – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Adaptive functioning (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: Brief Praxis Test)												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	No significant differences in Brief Praxis Test scores between antioxidant and placebo groups			⊕⊕○○ LOW	IMPORTANT	
Adaptive functioning (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: DMR [sum of social skills])												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	No significant differences in DMR sum of social scores scores between antioxidant and placebo groups			⊕⊕○○ LOW	IMPORTANT	
Adaptive functioning (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: Bristol Activities of Daily Living Scale )												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	No significant differences in Bristol Activities of Daily Living Scale scores between antioxidant and placebo groups			⊕⊕○○ LOW	IMPORTANT	
Any serious adverse event (incapacitation and/or inability to sustain daily activities) (all levels of learning disabilities) (follow up: mean 104 weeks; assessed with: [ITT/analysed as randomised])												
1	randomised trials	serious <sup>1</sup>	not serious	not serious	serious <sup>2</sup>	none	14/29 (48.3%)	11/29 (37.9%)	RR 1.27 (0.70 to 2.32)	<b>102 more per 1000</b> (from 114 fewer to 501 more)	⊕⊕○○ LOW	IMPORTANT

1. Risk of selective outcomes bias.
2. Sample size less than optimal information size (<400 for continuous outcomes or <300 for dichotomous outcomes).

CONFIDENTIAL